166 related articles for article (PubMed ID: 35840667)
1. Loss-of-function of the hippo transducer TAZ reduces mammary tumor growth through a myeloid-derived suppressor cell-dependent mechanism.
Shen H; Zhang Y; Kramer ED; Katsuta E; Wan Y; Chen Y; Wang J; Zhang Y; Matsuzaki J; Frangou C; Abrams SI; Zhang J
Cancer Gene Ther; 2022 Nov; 29(11):1791-1800. PubMed ID: 35840667
[TBL] [Abstract][Full Text] [Related]
2. TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment.
Gershoni A; Hassin O; Nataraj NB; Baruch S; Avioz-Seligman A; Pirona AC; Fellus-Alyagor L; Meir Salame T; Mukherjee S; Mallel G; Yarden Y; Aylon Y; Oren M
Mol Oncol; 2023 Dec; 17(12):2675-2693. PubMed ID: 37716913
[TBL] [Abstract][Full Text] [Related]
3. TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
Yang L; Wang B; Jiao X; Zhou C; Chen S; Gao X; Sun W; Song S; Li J; Liu J; Wang Y; Liu P
Breast Cancer Res; 2021 Sep; 23(1):89. PubMed ID: 34488828
[TBL] [Abstract][Full Text] [Related]
4. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
[TBL] [Abstract][Full Text] [Related]
5. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
7. Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
Wang Z; Wang F; Ding XY; Li TE; Wang HY; Gao YH; Wang WJ; Liu YF; Chen XS; Shen KW
Cancer Lett; 2022 Feb; 527():174-190. PubMed ID: 34929335
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
9. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
[TBL] [Abstract][Full Text] [Related]
10. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
11. Hsa_circ_0091074 regulates TAZ expression via microRNA‑1297 in triple negative breast cancer cells.
Hu J; Ji C; Hua K; Wang X; Deng X; Li J; Graham D; Fang L
Int J Oncol; 2020 May; 56(5):1314-1326. PubMed ID: 32319577
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
Mehdizadeh R; Shariatpanahi SP; Goliaei B; Rüegg C
Sci Rep; 2023 Apr; 13(1):5875. PubMed ID: 37041172
[TBL] [Abstract][Full Text] [Related]
13. ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
Kumar S; Wilkes DW; Samuel N; Blanco MA; Nayak A; Alicea-Torres K; Gluck C; Sinha S; Gabrilovich D; Chakrabarti R
J Clin Invest; 2018 Nov; 128(11):5095-5109. PubMed ID: 30295647
[TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer.
Adewunmi O; Shen Y; Zhang XH; Rosen JM
Cancer Immunol Res; 2023 Nov; 11(11):1462-1479. PubMed ID: 37603945
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
Dominguez C; McCampbell KK; David JM; Palena C
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093275
[TBL] [Abstract][Full Text] [Related]
16. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
17. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
18. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
[TBL] [Abstract][Full Text] [Related]
19. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
20. Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer.
Pomatto-Watson LCD; Bodogai M; Carpenter M; Chowdhury D; Krishna P; Ng S; Bosompra O; Kato J; Wong S; Reyes-Sepulveda C; Bernier M; Price NL; Biragyn A; de Cabo R
Geroscience; 2022 Oct; 44(5):2471-2490. PubMed ID: 35996062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
